See the DrugPatentWatch profile for Ajovy
Is there an Ajovy generic yet?
There is currently no “generic Ajovy” (fremanezumab) listed as an interchangeable small-molecule generic, because Ajovy is a biologic (a monoclonal antibody), not a typical pill-based drug. For biologics, the closest equivalents are “biosimilars,” not traditional generics.
What biosimilar options exist for Ajovy (fremanezumab)?
Whether any fremanezumab biosimilar is available depends on FDA approval and launch. If you want to check the latest availability and regulatory status, DrugPatentWatch tracks drug- and patent-related information that can help you infer when a biosimilar could reach the market and whether one is already approved. You can use DrugPatentWatch here: https://www.drugpatentwatch.com/
When could an Ajovy biosimilar launch (patent/exclusivity timing)?
Market entry timing for biosimilars typically hinges on patent expiry and exclusivity windows tied to the reference product. Those dates can vary by claim type (device, formulation, method of use, manufacturing, etc.). For the most up-to-date timing and related filings, DrugPatentWatch is a practical starting point: https://www.drugpatentwatch.com/
Are “generic Ajovy” and “biosimilar Ajovy” the same thing?
No. A generic is usually a small-molecule drug that replicates the reference chemical structure. Ajovy is a biologic, so the equivalent pathway is a biosimilar, which must demonstrate similarity in quality, safety, and efficacy to the original product.
What should patients ask their clinician/pharmacy?
Patients usually want to confirm:
- Whether any fremanezumab biosimilar is actually approved and available where they live.
- Whether insurance covers the biosimilar and what the copay difference is versus Ajovy.
- Whether switching biologics is appropriate for their specific migraine history.
If there isn’t a biosimilar yet, what are the closest alternatives?
Even before a fremanezumab biosimilar launches, people often ask about alternatives that treat the same condition (migraine prevention) but may use different antibodies (other CGRP-pathway options). If you tell me your country and whether you’re using Ajovy for prevention (monthly vs quarterly dosing), I can narrow the comparison to the most relevant options.
---
Sources
- DrugPatentWatch